HealthTech’s moment is real, but it comes with a catch

Two things are true in HealthTech right now, on both sides of the Atlantic. There’s more investment and more regulatory appetite in the sector than there’s been in years – and it’s flowing only to companies that can prove they’re compliant, transparent, and built to hold up under scrutiny.

In the UK, the NHS has committed up to £10bn to technology and digital transformation by 2028/29. But for NHS procurement the blocker was never ambition – it’s technical debt in legacy systems and a trust barrier that clinicians themselves have to clear, not just central procurement. New procurement rules are casting the net wider, but getting through still rests entirely on transparency and compliance.

In the US, the story is sharper still. On 18 August 2026, the FDA published its first-ever discussion paper on regulating generative AI-enabled medical devices, proposing a real framework for assessing risk, with public comment open until 19 October. It’s a rare, open invitation from a major regulator to help shape the rules before they’re fixed. Capital is following the same pattern: US digital health startups raised $7.4bn in the first half of 2026 alone, up on the year before. The money is here, for companies that can demonstrate they’ve thought about safety and trust as seriously as they’ve thought about the product.

Neither market is short of appetite for HealthTech. What’s changed is what companies have to prove to earn a share of it: not just a working product, but one whose story, evidence and design can survive being questioned by a regulator, a trust board, or an investor doing real diligence.

We believe that to be a design problem before it’s a compliance one. A product that earns trust looks and behaves differently from one that merely works – in how it explains itself, how it handles evidence, how it carries a user through the moments that matter. It’s what we research, design, test and build at Studiomade, and it’s the difference between a product that demos well and one that survives scrutiny. If you’re building in HealthTech and want yours to hold up, let’s talk.